吉非替尼治疗EGFR基因突变非小细胞肺癌的疗效及对生存情况的影响因素分析

The efficacy and influencing factors of survival in patients treated with gefitinib in non-small cell lung cancer combined with EGFR mutation status

目的探讨吉非替尼治疗EGFR基因突变非小细胞肺癌患者的疗效以及对生存情况的影响因素分析。方法选取我院2010年3月~2012年3月收治的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者63例,所有患者均给予口服吉非替尼治疗,250mg/次,1次/d,直至患者肿瘤病情有一定的进展或出现不可耐受的毒副作用而停药。比较发生EGFR基因突变(观察组)和未发生EGFR基因突变(对照组)的非小细胞肺癌患者之间的临床疗效及不良反应情况。结果观察组腺癌治疗的有效率(57.9%)要明显高于对照组(17.6%),差异具有统计学意义(P<0.05)。观察组治疗鳞癌(70.0%)的有效率明显高于对照组(14.3%),差异具有统计学意义(P<0.05)。观察组治疗Ⅲb期(75.0%)、Ⅳ期(53.8%)的总有效率明显高于对照组(16.7%,13.0%),差异具有统计学意义(P<0.05)。结论吉非替尼治疗EGFR基因突变的非小细胞肺癌患者具有显著的效果,并且不良反应发生率较低,值得在临床推广应用。

Objective To evaluate the efficacy and influencing factors of survival in patients with non-small cell lung cancer therapy combined with gefitinib EGFR mutation status. Methods 63 cases non-small cell carcinoma were collected in our hospital from Mar 2010 to Mar 2012. 29 cases were in the control group, all patients were given oral gefitinib treatment, 250mg, taken once a day until the disease had some progression or patients had intolerable side effects and withdrawal. 34 cases were in observation group, use of conventional chemotherapy treatment. Compared the clinical efficacy and adverse reactions in two groups. Results The treatment group adenocarcinoma (57.9%), squamous cell carcinoma (70.0%) of efficiency was sig-nificantly higher than control group(17.6%, 14.3%), and the difference was statistically significant (P<0.05). Phase Ⅲ b ob-servation group (75.0%),Ⅳperiod (53.8%) of the total efficiency was significantly higher than control group (16.7%, 13.0%), and the difference was statistically significant (P<0.05). Conclusion Compared with other treatment methods, treatment with gefitinib for patients with EGFR mutations in non-small cell cancer has a better effect, and less adverse reactions than other methods, it's worth to be applied in clinic.